WINSTON-SALEM, N.C., Oct. 14 /PRNewswire/ -- Plureon Corporation ("Plureon") today announced that it has entered into an agreement with BD (Becton, Dickinson and Company) in the field of diabetes research and development using Plureon's platform stem cell technology. Plureon's stem cells may be obtained from placental tissues that are usually discarded as medical waste after birth.
Under the agreement, BD will sponsor Plureon's research efforts for up to three years and will be responsible for further development of the technology. Plureon retains rights to provide future manufacturing and medical education support to BD.
Mr. Hal Eason, Chairman, President and CEO of Plureon, said, "We are extremely pleased to have BD as our partner in the field of diabetes. BD is a world leader in diabetes care, with an excellent understanding of patients, researchers and practitioners. BD also has unique technology assets to accelerate the research and development of Plureon's technology."
Plureon is a privately held biotechnology company based in Winston-Salem, North Carolina. Plureon has licensed from Children's Hospital Boston (a Harvard Medical School teaching affiliate) the exclusive worldwide rights to its patents pertaining to a novel type of stem cell discovered at the hospital's Laboratory for Cell Therapy and Tissue Engineering. Plureon's stem cells are not sourced from human embryonic tissues, yet may be differentiated into many other cell types, including bone, cardiac muscle, nerves, liver and pancreatic cells.
(336) 499 2673
CONTACT: Hal Eason, Plureon Corporation, +1-336-499-2673, email@example.com